$TAYD

Taylor Devices Inc (TAYD) Shares Fall 3.4% -- What GF Score of 8

Taylor Devices Inc (TAYD) shares fell 3.4% to $62.95. GuruFocus estimates the stock is overvalued at 36.6% above its intrinsic value of $46.10. TAYD has a GF Score of 89/100, with strong financial health and growth but weak valuation. Insiders sold $0.9M in shares over the past year. The P/E ratio is 24.0x, higher than its 5-year median of 16.2x.

Original reporting
Published Sep 29, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TAYD
Bearish
medium confidence
Mentioned
$TAYD
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TAYDBearishLow
01

Why it matters

The overvaluation and insider sell‑off may prompt short sellers, while the high growth scores could keep some investors interested.

02

Market read

The piece offers a valuation perspective but adds little new material; relevance for traders is modest.

03

What to watch

Potential upcoming product launches or contract wins not covered in the article could offset valuation concerns.

Relevance 4/10Novelty 2/10Timing: today

Background

Taylor Devices Inc (TAYD) is a small‑cap industrial equipment maker whose stock has shown volatility. The article provides a valuation snapshot from GuruFocus.

Company-level read

Ticker impact

$TAYDBearishMedium confidence
Context

Article reports a 3.4% price decline and notes the stock is trading 36.6% above its GF Value, indicating overvaluation and recent insider selling.

Expected impact

likely pressure as the market prices in valuation concerns and insider sell‑off

Evidence & confidence

High GF Score masks a low valuation rank; insiders have sold $0.9M with no buying, and the stock is above intrinsic value, which typically leads to pull‑backs.

Market effects

Limited; valuation concerns are company‑specific and do not signal broader sector trends.

None; the story is confined to the individual stock.

None

Counterpoint

Despite overvaluation, the strong GF Score and growth metrics could attract momentum buyers.

Key entities

  • Taylor Devices Inc

    Subject of the article; US‑listed ticker TAYD.

Related articles

$BNTXMed

BioNTech SE (BNTX) Posts Phase 2 NSCLC Data: 36.7% cORR, 6.9-Mo PFS

BioNTech SE (BNTX) reported Phase 2 data for pumitamig plus docetaxel in advanced non-small cell lung cancer (NSCLC), showing a 36.7% confirmed objective response rate and median progression-free survival of 6.9 months. The results suggest potential improvements over current standards of care, with manageable safety. BioNTech aims to advance the treatment into ongoing Phase 3 trials.

$BNTXMed

BioNTech and Bristol Myers Squibb's lung cancer drug combo showed a median of 6.9 months before disease worsened.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data showing their lung cancer drug combo, pumitamig plus docetaxel, achieved a 36.7% response rate and 6.9-month median progression-free survival in NSCLC patients who progressed after immunotherapy. The trial involved 50 patients, with 33 still on treatment. The companies are advancing multiple Phase 3 trials for pumitamig in various lung cancer settings.

$JNJMed

At one dose, 77% of patients on Johnson & Johnson's experimental drug saw a prostate cancer marker fall by 50% or more.

Johnson & Johnson's experimental drug JNJ-6143 showed promising results in a Phase 1 study, with 77% of patients achieving a 50% or greater reduction in PSA levels. The drug targets prostate cancer cells through a novel mechanism. The 50-mg dose will advance to further clinical development, including a Phase 2 study. The company highlights the significant unmet needs in advanced prostate cancer treatment.